Description
Delta-sleep-inducing peptide (DSIP) is a neuropeptide with amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and molecular mass 848.81 g/mol. DSIP occurs in both free and bound forms in the hypothalamus, limbic system and pituitary as well as various peripheral organs, tissues and body fluids. In the pituitary it co-localises with many peptide and non-peptide mediators such as corticotropin-like intermediate peptide (CLIP), adrenocorticotrophic hormone (ACTH), melanocyte-stimulating hormone (MSH), thyroid-stimulating hormone (TSH) and melanin concentrating hormone (MCH). Delta-sleep-inducing peptide is abundant in the gut secretory cells and in the pancreas where it co-localises with glucagon.
Uses
Delta-sleep-inducing peptide (DSIP) was isolated, characterized, and synthesized more than 6 years ago. It can help relieve stress and aches that keep you from restful sleep. It was first proposed as a sleep-peptide and this remains the prevalent impression of its function. DSIP is a natural sleep-promoting nonapeptide with a few beneficial functions. The peptide has been used to treat poor sleep, pain conditions, stress-related symptoms, and more. Delta-Sleep Inducing Peptide trifluoroacetate salt H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH trifluoroacetate salt is a useful research chemical compound.
Uses
DSIP is thought to increase sleep regulation, reduce motor activity to improve deep sleep, stimulate ACTH and LH levels, and reportedly normalize blood pressure. DSIP can change the serum level of some hormones, such as adrenocorticotropic hormone, somatostatin, serotonin, etc.
Definition
Emideltide or DSIP is a nonapeptide that is found in neurons, peripheral organs, and plasma. This neuropeptide induces mainly delta sleep in mammals. In addition to sleep, the peptide has been observed to affect electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor patterns, hormonal levels, psychological performance, and the activity of neuropharmacological drugs including their withdrawal.
benefits
Can restore disturbed sleep patterns;Can promote LH and GH release;Can reduce persistent/chronic pain;Can modulate cortisol production.
benefits
Delta sleep-inducing peptide (DSIP), which suppresses excess production of free radicals in the CNS and prevents neuron death during the body’s response to stress. DSIP activates oxidative phosphorylation and increases the resistance of brain neurons to hypoxia in vitro. It decreases the sensitivity of neuron receptors to the excitatory actions of glutamate. Thus, DSIP helps to prevent excitotoxicity, which may underlie its neuroprotective action in cerebral ischemia[1].
References
[1] E. Koplik. “Delta sleep-inducing peptide and Deltaran: Potential approaches to antistress protection.” Neuroscience and Behavioral Physiology 38 1 (2008): 953–957.
Physiological effects
Delta sleep-inducing peptide (DSIP) has several physiological effects in addition to its ability to promote sleep in animals. It is also involved in neuroendocrine regulation and release of anterior pituitary hormones. In rodents and humans, Delta sleep-inducing peptide (DSIP) influence in the secretion of adrenocorticotropic hormone (ACTH), luteinizing hormone (LH) and growth hormone (GH). It also plays a role in the regulation of the circadian rhythms and and can help restore disturbed patterns of sleep.
Description
DSIP Synthetic is a single, non-glycosylated polypeptide chain containing 15 amino acids, having a molecular mass of 1419.55 Dalton and a Molecular formula of C
62H
98N
16O
22.
Background
Delta Sleep-Inducing Peptide (DSIP), also known as Sleep-Promoting Peptide, is a neuropeptide that has been the subject of extensive research due to its potential role in sleep regulation, stress response, and neuroprotection. This nonapeptide, first isolated from the cerebral venous blood of rabbits during sleep, has been shown to induce slow-wave sleep, modulate pain perception, and exhibit potential antioxidant and immunomodulatory properties.
DSIP's primary function is its interaction with the sleep regulatory system. By modulating the release of certain neurotransmitters, DSIP can influence sleep patterns, particularly promoting slow-wave sleep, the most restorative stage of sleep. Studies by Kovalzon et al. (2011) have demonstrated that DSIP can enhance sleep quality in rats, suggesting potential applications in sleep disorders and the promotion of healthy sleep patterns.
In addition to its sleep-inducing effects, DSIP has been shown to possess neuroprotective properties. Research by Zolotarev et al. (2014) found that DSIP could protect neurons from oxidative stress, suggesting potential applications in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
Given its sleep-inducing and neuroprotective effects, DSIP has been proposed as a potential therapeutic agent for a variety of conditions, including sleep disorders, chronic pain, and neurodegenerative diseases. For instance, a study by Spong et al. (2016) found that DSIP could improve sleep quality in patients with chronic insomnia, indicating its potential as a therapeutic agent in the treatment of sleep disorders.
While research on DSIP is promising, it is important to note that most studies have been conducted in animals or in vitro. More research is needed to fully understand the potential effects and applications of DSIP in humans. However, the existing body of research suggests that DSIP could be a promising tool in the treatment of sleep disorders, chronic pain, and neurodegenerative diseases.
